

REMARKS

This Preliminary Amendment is being filed to voluntarily amend certain of the claims in order to more distinctly point out the features and characteristics of the claimed subject matter. Upon entry of the present amendments, claims 1-15 are presently pending.


Applicants have amended claims 1-3, 9, and 14 to more distinctly point out that the claimed antibody specifically binds P210 BCR-ABL fusion protein. Dependent claim 4 has been amended to recite that the claimed antibody is suitable for use in certain preferred cell-based assays, such flow cytometry. Lastly, dependent claim 15 has been amended to recite that the claimed kit comprises at least one "detectable" antibody of claim 1.

These amendments are supported throughout the specification and claims as originally filed, *e.g.* at p. 9, lines 17-23; p. 14, lines 5-21; p. 14, line 26 to p. 15, line 9; p. 20, lines 9-11; and Examples 3 and 4. These amendments do not introduce new matter.

Applicants believe no fees are due in connection with the present filing. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of the same, to Deposit Account No. 50-1774, Ref. No. CST-214.

The present claims are believed to be in condition for immediate allowance. Early and favorable consideration leading to prompt issuance of these claims is earnestly solicited. If there are any questions regarding these amendments, the Examiner is requested to call the undersigned attorney at the telephone number provided.

Respectfully submitted,



James Gregory Cullem, J.D., Reg. No. 43,569
Intellectual Property Counsel
CELL SIGNALING TECHNOLOGY, INC.
Beverly, MA 01915

Date: June 16, 2005